#stayhome Maintain the distance, wash your hands, and follow instructions from the health authorities.
RSS   Newsletter   Contact   Advertise with us

Immunome names Michael J. Morin as president and chief scientific officer

Share on Twitter Share on LinkedIn
Staff writer | Philadelphia, Pa., USA | March 9, 2016
ImmunomeMarch 9, 2016, Philadelphia, Pa., USA - Immunome, a biotechnology company, announced that industry veteran Michael J. Morin has joined Immunome as president and chief scientific officer.
Dr. Morin offers more than 25 years in pharmaceutical research and development with a proven track record of developing approvable cancer therapy candidates.

Dr. Morin’s oncology career spans academia and industry, including 17 years at Pfizer where he served as vice president of global research and development overseeing immunology, anti-bacterials and cancer drug discovery in Groton, CT.

Approximately 40 clinical candidates were discovered under Dr. Morin’s leadership at Pfizer. Following his time at Pfizer, Dr. Morin worked as an advisor to venture-backed biotechnology and publicly held pharmaceutical companies.

Dr. Morin also actively participates in a variety of cancer research organizations, including as long-standing co-chair of the NCI Experimental Therapeutics (NExT) review panel, chair of the Drug Discovery Initiative of the Children’s Tumor Foundation, and as a member of the scientific advisory board of the Ontario Institute of Cancer Research.

Immunome’s founder and former chief scientific officer, Scott Dessain, MD, PhD, assumes the role of chief technology officer.

 LATEST MOVES FROM Pennsylvania